{"id":477157,"date":"2020-04-01T11:48:02","date_gmt":"2020-04-01T11:48:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477157"},"modified":"2020-04-01T11:48:02","modified_gmt":"2020-04-01T11:48:02","slug":"parkinsons-disease-pipeline-insights-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/parkinsons-disease-pipeline-insights-2020_477157.html","title":{"rendered":"Parkinson\u2019s Disease Pipeline Insights, 2020"},"content":{"rendered":"
\"Parkinson\u2019s<\/a><\/p>\n
\n
Parkinson\u2019s Disease Pipeline<\/div>\n<\/div>\n<\/div>\n
“Parkinson\u2019s Disease Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Parkinson\u2019s Disease market. A detailed picture of the Parkinson\u2019s Disease pipeline landscape is provided, which includes the disease overview and Parkinson\u2019s Disease treatment guidelines.<\/div>\n

DelveInsight launched a new report on Parkinson’s Disease Pipeline Insights, 2020<\/a><\/p>\n

Some of the key facts of the report:-<\/strong><\/p>\n

Some pharmaceutical and biotech companies like Prevail Therapeutics, Axovant Gene Therapies, Neurocrine Biosciences\/Voyager Therapeutics, Denali Therapeutics, and others are researching new therapies that target other aspects of pathology, namely genetic mutations, and Lewy bodies (a hallmark feature of Parkinson’s disease).<\/p>\n

Apart from these, other small molecule that are under development and expected to enter the market includes Istradefylline (Kyowa Kirin), Opicapone (Neurocrine Biosciences), P2B001 (Pharma Two B Ltd), LY03003 (Luye Pharma), ABBV-951 (AbbVie), APL-130277 (Sunovion Pharma), Accordion Pill (Intec Pharma), Apomorphine infusion (US WorldMeds LLC), IPX203 (Impax Laboratories), IRL752 (Integrative Research Laboratories AB), ND0612 (NeuroDerm), ITI-214 (Intra-Cellular Therapies), Nilotinib (Novartis), etc. The expected launch of these therapies during the forecasted period are expected to impact the market size of Parkinson’s Disease (PD) in the upcoming years.<\/p>\n

Neurocrine Biosciences is developing a new gene therapy VY-AADC, which is currently being evaluated in patients who have been diagnosed with Parkinson’s disease for at least 4 years, are not responding adequately to oral medications, and have at least 3 hours of “off” time during the day, as measured by a validated self-reported patient diary. It is developed by Neurocrine Biosciences and Voyager Therapeutics as part of strategic collaboration.<\/p>\n

Istradefylline (Nouriast) is a selective agonist at the A2A receptor that is administered orally. It reduces dyskinesia resulting from long-term treatment with classical anti-parkinson drugs such as levodopa. The drug is already approved in Japan in 2013, and the company has filed a new drug application for its approval in the US.<\/p>\n

Opicapone (Ongentys) is a new long-acting, peripherally selective, once- daily catechol-O-methyl transferase inhibitor. Opicapone is licensed in Europe for the treatment of Parkinson’s disease. Neurocrine has filed an application for its approval in the US.<\/p>\n

P2B001 is a low-dose, sustained release combination of pramipexole and resagiline. This new approach takes advantage of the well-known therapeutic effects and good safety profile of both Parkinson’s drugs and combines it with Pharma Two B’s proprietary sustained-release formulation. The company believes that P2B001 has the potential to become a leading therapy for early stage PD and claims that once approved, it is expected to provide early-stage Parkinson’s patients with effective treatment with an improved safety profile.<\/p>\n

Request for sample pages:- https:\/\/www.delveinsight.com\/sample-request\/parkinsons-disease-pipeline-insight<\/a><\/p>\n

 \"\"<\/strong><\/p>\n

Scope of the Report<\/strong><\/p>\n